- Brief Report
- Open Access
Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia
© The Author(s) 2012
- Received: 19 December 2011
- Accepted: 11 January 2012
- Published: 4 February 2012
This study reports a case of bilateral rifabutin-associated uveitis in a child with a history of acute myeloid leukemia.
We utilized a clinical case description and brief discussion.
A 17-year-old girl presented with acute bilateral anterior uveitis, a hypopyon in the left eye, and moderate bilateral vitritis. She had a history of acute myeloid leukemia status post-allogeneic hematopoietic stem cell transplant 5 years earlier. She was receiving rifabutin for a biopsy-proven Mycobacterium avium complex pulmonary infection. Work up for infectious and neoplastic etiologies was negative. The uveitis initially responded to topical corticosteroids, but recurred when the drops were tapered. Fluorescein angiography demonstrated diffuse vasculitis of small retinal vessels and cystoid macular edema. After rifabutin was discontinued, the uveitis and vasculitis slowly resolved.
Fluorescein angiography demonstrated widespread retinal vasculitis which is a rare manifestation of rifabutin-associated uveitis.
- Retinal vasculitis
- Cystoid macular edema
Rifabutin is a semisynthetic derivative of rifampin that is effective for the prophylaxis and treatment of Mycobacterium avium complex (MAC) infection. It is frequently used in immunocompromised patients with human immunodeficiency virus (HIV) or a history of organ or stem cell transplantation. Anterior uveitis and hypopyon are well-recognized and frequently reported complications of rifabutin treatment; however, posterior involvement is relatively rare [1, 2]. Here, we describe a case of rifabutin-associated panuveitis in a young patient with a history of acute myeloid leukemia.
A 17-year-old Eritrean girl presented with a 5-day history of redness, tearing, and photophobia which started in her right eye (OD) and then involved her left (OS). She recalled similar, but less severe symptoms over the 2 months prior to presentation. Her medical history was significant for acute myeloid leukemia diagnosed 5 years earlier. She was treated with chemotherapy and received an allogeneic hematopoietic stem cell transplant 6 months after diagnosis. She developed graft-versus-host-disease (GVHD) of the gastrointestinal tract, lungs, and skin with mild ocular surface involvement, but these issues were stable at the time of presentation to the eye clinic.
Anterior uveitis and hypopyon are the most frequent manifestations of rifabutin-associated uveitis; however, severe cases may develop dense vitritis with large yellow-white opacities or panuveitis resembling endophthalmitis [3, 4]. Despite the strong association with rifabutin, infectious, autoimmune and neoplastic etiologies should still be investigated depending on the clinical situation. Examination of aqueous humor and/or vitreous via culture, cytology, or polymerase chain reaction can help rule out infection or malignancy.
Although mild to moderate vitritis frequently develops in rifabutin-associated uveitis, posterior involvement is less frequent [5–7]. Similar to the previous cases, our patient presented with uveitis several months after the start of rifabutin and responded quickly to topical corticosteroids and discontinuation of rifabutin. Of the four cases described by Skolik, only one patient had diffuse vasculitis on FA; the others had mild peripheral vasculitis or perivascular sheathing. Of note, the patient with diffuse FA changes was immunocompetent, whereas the other patients had acquired immunodeficiency disease syndrome (AIDS) and CD4 counts less than 100 cells/mm3. In each of the single case reports by Arevalo and Vaudaux, the rifabutin-associated uveitis was unilateral and the posterior findings were focal. Arevalo’s patient had AIDS and a CD4 count of 3 cells/mm3; a focal area of sclerosed retinal vessels was noted after intraocular injections of vancomycin and gentamicin for presumed endophthalmitis. In the case from Vaudaux, the patient had been treated with systemic prednisone for chronic obstructive pulmonary disease 4 months prior to developing uveitis, but was otherwise immunocompetent. The FA and ocular coherence tomography (OCT) confirmed unilateral cystoid macular edema. In our immunocompetent patient, the vasculitis was notable for its diffuse and bilateral nature and slow resolution after the discontinuation of rifabutin.
Rifabutin-associated uveitis was initially described in HIV-positive patients, but it may also occur in patients who are immunocompetent . Only a few pediatric cases have been reported ; however, due to the possible association with low body weight , weight-based dosing has been suggested as a strategy to prevent uveitic complications. Our patient weighed 42.5 kg, and uveitis developed after the rifabutin was restarted at twice the initial dose. It is unclear whether the lack of systemic immunomodulatory medications influenced the onset of uveitis during the second course of rifabutin since patients have developed rifabutin uveitis while iatrogenically immunosuppressed after transplantation . Perhaps an intact immune system predisposed our patient to develop more extensive retinal vasculitic changes.
We describe a case of rifabutin-associated hypopyon uveitis in a young immunocompetent patient with an unusual degree of diffuse bilateral retinal vasculitis. While the anterior chamber and vitreous inflammation disappeared rapidly after discontinuation of rifabutin, resolution of the retinal vasculitis took several months. Fluorescein angiography helped assess the extent and severity of uveitis as well as guide the topical corticosteroid taper.
This research was supported by the Intramural Research Program of the National Institutes of Health and the National Eye Institute.
- Jacobs DS, Piliero PJ, Kuperwaser MG, Smith JA, Harris SD, Flanigan TP, Goldberg JH, Ives DV (1994) Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection. Am J Ophthalmol 118(6):716–722PubMedView ArticleGoogle Scholar
- Shafran SD, Singer J, Zarowny DP, Deschênes J, Phillips P, Turgeon F, Aoki FY, Toma E, Miller M, Duperval R, Lemieux C, Schlech WF 3rd (1998) Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 177(1):252–255PubMedView ArticleGoogle Scholar
- Rifai A, Peyman GA, Daun M, Wafapoor H (1995) Rifabutin-associated uveitis during prophylaxis for Mycobacterium avium complex infection. Arch Ophthalmol 113(6):707PubMedView ArticleGoogle Scholar
- Chaknis MJ, Brooks SE, Mitchell KT, Marcus DM (1996) Inflammatory opacities of the vitreous in rifabutin-associated uveitis. Am J Ophthalmol 122(4):580–582PubMedView ArticleGoogle Scholar
- Arevalo JF, Russack V, Freeman WR (1997) New ophthalmic manifestations of presumed rifabutin-related uveitis. Ophthalmic Surg Lasers 28(4):321–324PubMedGoogle Scholar
- Vaudaux JD, Guex-Crosier Y (2002) Rifabutin-induced cystoid macular oedema. J Antimicrob Chemother 49(2):421–422PubMedView ArticleGoogle Scholar
- Skolik S, Willermain F, Caspers LE (2005) Rifabutin-associated panuveitis with retinal vasculitis in pulmonary tuberculosis. Ocul Immunol Inflamm 13(6):483–485PubMedView ArticleGoogle Scholar
- Jewelewicz DA, Schiff WM, Brown S, Barile GR (1998) Rifabutin-associated uveitis in an immunosuppressed pediatric patient without acquired immunodeficiency syndrome. Am J Ophthalmol 125(6):872–873PubMedView ArticleGoogle Scholar
- Bhagat N, Read RW, Rao NA, Smith RE, Chong LP (2001) Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Ophthalmology 108(4):750–752PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.